公开(公告)号：US20240075165A1

公开(公告)日：2024-03-07

申请号：US17988742

申请日：2022-11-16

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: A61K48/00 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

CPC classification number: A61K48/0066 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/215 ,  A61K48/0033 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34 ,  A61K38/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  C12N2770/18022 ,  C12N2770/18034 ,  C12N2770/18071 ,  C12N2770/20034

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US11878055B1

公开(公告)日：2024-01-23

申请号：US18341590

申请日：2023-06-26

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin ,  Kayvon Modjarrad

IPC: A61K9/51 ,  A61K31/7105 ,  A61K31/7115 ,  A61K39/215 ,  A61P31/14 ,  C07K14/005 ,  A61K39/00

CPC classification number: A61K39/215 ,  C07K14/005 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/70 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20071

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.

公开(公告)号：US20230075979A1

公开(公告)日：2023-03-09

申请号：US17698829

申请日：2022-03-18

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: A61K39/215 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K9/51 ,  A61P31/14 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20220356223A1

公开(公告)日：2022-11-10

申请号：US17621396

申请日：2020-06-23

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Sina Fellermeier-Kopf ,  Alexander Muik ,  Mathias Vormehr ,  Lena Mareen Kranz

IPC: C07K14/55 ,  A61P35/00

Abstract: The invention relates to variants of interleukin-2 (IL2). In particular, the invention relates to a polypeptide comprising a mutein of human IL2 or of a functional variant of human IL2, wherein the human IL2 or functional variant thereof is substituted such that affinity for the βγ IL2 receptor complex (IL2Rβγ) is enhanced. In one embodiment, the human IL2 or functional variant thereof is further substituted such that affinity for the αβγ IL2 receptor complex (IL2αβγ) is reduced. In one embodiment, the polypeptide activates effector T cells over regulatory T cells. The invention also relates to polynucleotides coding for the polypeptides of the invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or prophylactic methods of treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions and medical preparations comprising the polypeptides, polynucleotides, host cells or pharmaceutical compositions.

公开(公告)号：US11932693B2

公开(公告)日：2024-03-19

申请号：US18315686

申请日：2023-05-11

Applicant: BioNTech SE ,  Genmab A/S

Inventor： Ugur Sahin ,  Sina Fellermeier-Kopf ,  Friederike Gieseke ,  Karsten Beckmann ,  Claudia Paulmann ,  Alexander Muik ,  Ivan Kuzmanov ,  Esther Cornelia Wilhelmina Breij ,  Patricia Garrido Castro ,  Jordan Blum ,  Lars Guelen ,  Joost Neijssen ,  Bart-Jan De Kreuk ,  Richard Hibbert ,  Janine Schuurman ,  Aran Frank Labrijn

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  C07K2317/24 ,  C07K2317/92

Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.

公开(公告)号：US11925694B2

公开(公告)日：2024-03-12

申请号：US17698829

申请日：2022-03-18

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: A61P31/14 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61K48/00 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34 ,  A61K38/00

CPC classification number: A61K48/0066 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/215 ,  A61K48/0033 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34 ,  A61K38/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55555 ,  C12N2770/18022 ,  C12N2770/18034 ,  C12N2770/18071 ,  C12N2770/20034 ,  C12N2840/00

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20230338512A1

公开(公告)日：2023-10-26

申请号：US18071499

申请日：2022-11-29

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Asaf Poran ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai

IPC: A61K39/215 ,  A61K45/06

CPC classification number: A61K39/215 ,  A61K45/06 ,  A61K2039/53

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20230287088A1

公开(公告)日：2023-09-14

申请号：US18019787

申请日：2021-07-29

Applicant: BIONTECH SE

Inventor： Karsten Beckmann ,  Anna Carle ,  Sandra Prassl ,  Claudia Paulmann ,  Christiane Stadler ,  Georg Falck ,  Leyla Fischer ,  Alexander Muik ,  Ugur Sahin ,  Caroline Scharf

IPC: C07K16/10 ,  A61P31/14

CPC classification number: C07K16/10 ,  A61P31/14 ,  C07K2317/31 ,  C07K2317/92

Abstract: The present disclosure relates to a binding agent comprising a first and a second binding domain, wherein the first binding domain is capable of binding to a coronavirus spike protein (S protein) and the second binding domain is capable of binding to the coronavirus S protein, and wherein the first and second binding domains bind to different epitopes of the coronavirus S protein. Moreover, the disclosure relates to an antibody capable of binding to a coronavirus spike protein (S protein). The disclosure also relates to a nucleic acid such as RNA encoding the binding agent, in particular antibody, disclosed herein and a host cell transformed or transfected with said nucleic acid. Furthermore, the disclosure relates to a medical use of said binding agent, antibody, or nucleic acid. The agents and medical uses described herein are, in particular, useful for the prevention or treatment of coronavirus infection in a subject.

公开(公告)号：US20220273820A1

公开(公告)日：2022-09-01

申请号：US17565921

申请日：2021-12-30

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci ,  Gábor Boros ,  Azita Josefine Mahiny ,  Jonas Reinholz ,  Katalin Karikó

IPC: A61K48/00 ,  A61K9/127 ,  A61K39/215 ,  C12N7/00

Abstract: Disclosed herein are RNA polynucleotides comprising a 5′ Cap, a 5′ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.

公开(公告)号：US12208136B2

公开(公告)日：2025-01-28

申请号：US18186914

申请日：2023-03-20

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin ,  Kayvon Modjarrad

IPC: A61K39/215 ,  A61K9/127 ,  A61K39/145 ,  A61K45/06 ,  A61K47/26 ,  C12N15/86 ,  A61K39/00

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.